A randomized, placebo-controlled study of donepezil in poststroke aphasia.
We studied 26 patients in a randomized, placebo-controlled, double-blind parallel trial to evaluate the efficacy and safety of donepezil in chronic poststroke aphasia. Donepezil (10 mg/day) improved aphasia severity at endpoint (week 16) relative to placebo (p = 0.037).
Berthier
M L
ML
Centro de Investigaciones Médico-Sanitarias, University of Malaga School of Medicine, Spain. mberthier@terra.es
Green
C
C
Higueras
C
C
Fernández
I
I
Hinojosa
J
J
Martín
M C
MC
D000109:Acetylcholine / Q000378:metabolism; D000328:Adult; D001037:Aphasia / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D001921:Brain / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D002560:Cerebrovascular Circulation / Q000187:drug effects / Q000502:physiology; D000077265:Donepezil; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007189:Indans / Q000008:administration & dosage*; D007807:Language Tests; D008297:Male; D008875:Middle Aged; D009416:Nerve Regeneration / Q000187:drug effects / Q000502:physiology; D009434:Neural Pathways / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology; D018697:Nootropic Agents / Q000008:administration & dosage; D010880:Piperidines / Q000008:administration & dosage*; D010919:Placebos; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology; D013070:Speech Therapy; D020521:Stroke / Q000150:complications* / Q000503:physiopathology; D016896:Treatment Outcome
D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D010919:Placebos; D000077265:Donepezil; D000109:Acetylcholine